Hemab Therapeutics Q2 net loss widens to $24.2 million; cash totals $457.5 million
Hemab Therapeutics reported second quarter 2026 results, with a net loss of $24.2 million, or $0.80 per share, up from $12.2 million in the year-earlier quarter. Research and development and general and administrative expenses both rose, and the company says its cash will fund operations into 2029 after its May 2026 initial public offering. The filing gives no revenue or guidance figures, and the lower per-share loss mainly reflects a much larger share count.
Key points
- Net loss was $24.2 million, or $0.80 per share, for the quarter ended June 30, 2026, versus $12.2 million, or $12.91 per share, a year earlier.
- Research and development expenses were $20.3 million, compared with $12.9 million a year earlier; general and administrative expenses were $5.7 million, compared with $3.2 million.
- Cash, cash equivalents and marketable securities totaled $457.5 million at June 30, 2026, including net IPO proceeds of $317.2 million; the company expects this to fund operations into 2029.
The filing
Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.